OncoMatch/Clinical Trials/NCT05113368
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Is NCT05113368 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Regorafenib and Fulvestrant for ovarian cancer.
Treatment: Regorafenib · Fulvestrant — To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-angiogenesis therapy
Exception: bevacizumab allowed
Prior anti-angiogenesis therapy is not allowed except for bevacizumab
Cannot have received: regorafenib or other agents with similar multi-targeted kinase activity (regorafenib)
Prior use of regorafenib or other agents with similar multi-targeted kinase activity
Lab requirements
Blood counts
Platelet count >100000 /mm3, hemoglobin (Hb) >9 g/dL, absolute neutrophil count (ANC)> 1500/mm3
Kidney function
Serum creatinine ≤ 1.5 x ULN
Liver function
Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement); Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement)
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement); Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN with liver involvement); Serum creatinine ≤ 1.5 x ULN; Platelet count >100000 /mm3, hemoglobin (Hb) >9 g/dL, absolute neutrophil count (ANC)> 1500/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify